Bharat Immunological & Biological Corporation Ltd

A sharp decline in Bharat Immunological & Biological Corporation Ltd shares has pushed the stock to a fresh 52-week low of Rs 14.06 on 18 Sep 2026, marking a 7.21% drop over the past two sessions amid continued underperformance relative to its sector and benchmark indices.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 April 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 September 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024. However, the analysis and financial metrics discussed below reflect the company’s current position as of 04 September 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 13 August 2026, providing investors with the latest insights into its performance and prospects.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis below is based on the company’s current fundamentals, returns, and financial metrics as of 02 August 2026, providing investors with an up-to-date perspective on its investment potential.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 Apr 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 21 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis below presents the company’s current position as of 09 July 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Apr 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 Apr 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 17 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 Apr 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 26 May 2026, providing investors with the latest insights into its performance and prospects.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 Apr 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here represent the company’s current position as of 15 May 2026, providing investors with the latest insights into its performance and prospects.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Apr 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 04 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 Apr 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here represent the company’s current position as of 21 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical standing.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Apr 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 10 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

For the second consecutive session, Bharat Immunological & Biological Corporation Ltd has extended its decline, hitting a fresh 52-week low of Rs 14.62 on 30 Mar 2026. This latest drop comes amid a broader sector underperformance and persistent concerns over the company’s financial health.

Bharat Immunological & Biological Corporation Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 09 April 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

A sharp decline of 4.29% today dragged Bharat Immunological & Biological Corporation Ltd to a fresh 52-week low of Rs 15.55, extending its downward trajectory despite a brief two-day rally. This fall comes amid a broader market weakness, but the stock’s underperformance is notably more severe than its sector peers.

A sharp decline has pushed Bharat Immunological & Biological Corporation Ltd to a fresh 52-week low of Rs 15.66 on 23 Mar 2026, marking a significant 45.6% drop from its 52-week high of Rs 28.80. This fall comes amid a broader market downturn but is notably more severe than sector and benchmark indices, reflecting company-specific pressures.